Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL 1020 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| I | EXPERIMENTAL | BL - 1020 lowdose |
| II | EXPERIMENTAL | BL 1020 high dose |
| III | PLACEBO_COMPARATOR | - |
| IV | ACTIVE_COMPARATOR | Risperidone |
| 1 | EXPERIMENTAL | BL-1020 10 mg |
| 2 | EXPERIMENTAL | BL-1020 10-30 mg |
| 3 | ACTIVE_COMPARATOR | risperidone |
| Name | Type | Description |
|---|---|---|
| BL - 1020 | DRUG | 10 mg/day |
| Placebo | DRUG | Capsules |
| Risperidone | DRUG | Capsules |
| BL-1020 | DRUG | 10 mg |
| BL-1020 10-30 mg | DRUG | BL-1020 10-30 mg |
| BL 1020 High Dose | DRUG | BL 1020 High Dose |
Inclusion Criteria: * Patient is male or female, 18-65 years of age, inclusive. * If female, the patient must be post-menopausal, or if fecund, must be abstinent or practicing an established method of birth control such as hormonal preparations (e.g., oral contraceptive tablets, hormonal implant de...
Top 15 of 16 competitors
BL 1020 is an investigational small molecule developed by BioLineRx Ltd. for schizophrenia. It is a Phase 2 candidate that has been studied in three completed clinical trials enrolling a total of 670 participants. It has not been approved and remains in clinical development.
BL 1020 is being developed for the treatment of schizophrenia. One of its Phase 2 trials also enrolled patients with chronic schizophrenia or schizoaffective disorder. All studies of BL 1020 to date have been completed, and the drug remains investigational.
BL 1020 is developed by BioLineRx Ltd., which trades under the ticker BLRX. The company has sponsored three completed Phase 2 trials of the drug in schizophrenia, including a randomized, double-blind, placebo-controlled study and a long-term extension study.
BL 1020 is in Phase 2 development. All three of its clinical trials were Phase 2 studies, and all have been completed. There are currently no active trials of BL 1020, and the drug is not FDA approved.
BL 1020 has been evaluated in three completed Phase 2 trials: NCT00722176, a long-term safety, tolerability, and efficacy extension study; NCT00567710, a six-week randomized, double-blind, placebo-controlled study; and NCT00480571, a safety and tolerability study in hospitalized patients.
Yes. BL 1020, BL-1020, BL - 1020, and BL- 1020 all refer to the same investigational compound developed by BioLineRx Ltd. for schizophrenia. The variations are formatting differences in how the drug name is written.